logo/base Created with Sketch.

FibroScan® powered by CAP

CAP is the non-invasive reference parameter used as an aid to diagnose and monitor liver steatosis.

CAP is available as an option.

chevron chevron

Who is at-risk of fatty liver disease?

Most patients with the presence of a metabolic syndrome.
  • Type 2 diabetes 
  • Overweight and obesity
  • High cholesterol
  • High blood pressure
  • High triglycerides
Learn more

Advantages of CAP

CAP is unique, patented and validated for liver steatosis assessment1,2:
1,130 international and peer-reviewed articles support the use of CAP.

 

CAP is a guiding point for doctors and patients to improve monitoring of lifestyle change and therapeutic intervention.

 

CAP is a quantitative surrogate of liver steatosis expressed in decibel per meter (db/m).

Both LSM by VCTE® and CAP are measured simultaneously without lengthening the examination time.

 

CAP is available on the three FibroScan® probes (S+*, M+ and XL+).

Learn more

Continuous CAP

With SmartExam, improve reliability in the diagnosis and monitoring of steatosis with Continuous CAP for the management of fatty liver patients.

Learn more

Our liver health solutions

  • Liver Health Management

    Liver Health Management

    Cloud-based solution to assist clinicians in providing comprehensive liver care.

    chevron
  • Scores FibroScan® based

    FibroScan®-based Scores

    Enhance FibroScan® liver disease assessment with biological markers

    chevron
  • FibroScan® Guided VCTE

    Guided VCTE®

    Seamless liver health assessment for all

    chevron
  • FibroScan® Mini+ 430

    FibroScan® by echosens

    The non-invasive solution for comprehensive management of liver health

    chevron

CAP: tried and trusted

CAP provides a convenient and patient-friendly method to assess lipid turnover during lifestyle and dietary interventions to combat MASLD.

Publication Arslanow et al.

Clinical and Translational Gastroenterology, 2016

Lifestyle modification improves the hepatic steatosis, and CAP can be used to detect the improvement of hepatic steatosis during follow-up in patients with MASLD on lifestyle modification.

Publication Paul et al.

Arq Gastroenterol, 2018

The dietary intervention has a positive impact on CAP.

Publication Arslanow et al.

Clinical and Translational Gastroenterology, 2016

Discover the clinical evidence chevron

Request a demo!

Interested in FibroScan®?

Contact us

*CAP is not available on S+ probe in all countries.

1. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi:10.1016/j.jhep.2016.12.022.
2. Recio E, Cifuentes C, Macías J, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool or the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2013;25(8):905-911.doi:10.1097/MEG.0b013e32835f4c3d.

Products in the FibroScan® range are Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). These devices are designed for use in a medical practice in order to measure liver stiffness and ultrasound attenuation in patients with liver disease. Examinations with FibroScan® device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies.